At two years of follow-up, patients with a poorly functioning tricuspid valve in the heart who received the best available ...

TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...

The Society for Cardiovascular Angiography & Interventions (SCAI) has published a first-of-its-kind educational resource for interventional cardiologists and imaging specialists performing ...

Abbott (NYSE: ABT) today announced late-breaking data from its TRILUMINATE™ Pivotal trial that show the TriClip™ transcatheter edge-to-edge repair (TEER) system to treat tricuspid regurgitation (TR), ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.

To the Editor: In the TRISCEND II trial, Hahn and colleagues (Jan. 9 issue) 1 concluded that transcatheter tricuspid-valve replacement plus medical therapy was superior to medical therapy alone.

Ben McCullough met the 25 Edwards Lifesciences technicians who spent 20 hours hand-sewing 2,000 stitches to make a valve ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of ...

Payment will be provided when TTVR is delivered for an FDA-approved indication in the context of a CMS-approved study.

Abbott Laboratories (NYSE:ABT) recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid ...

Abbott Laboratories ABT recently unveiled favorable TRILUMINATE Pivotal trial data at the American College of Cardiology's Annual Scientific Session (ACC.25), held in Chicago. The data demonstrated ...